Clinical studies consistently demonstrate inferior outcomes with ICIs in <i>STK11</i>-mutant NSCLC, particularly in the presence of <i>KRAS</i> and <i>KEAP1</i> co-mutations. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.